Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
14.77
+0.23 (1.58%)
Nov 3, 2026, 4:00 PM EST - Market closed
Mesoblast Revenue
In the fiscal year ending June 30, 2026, Mesoblast had annual revenue of $120.25M with 599.21% growth. Mesoblast had revenue of $68.91M in the half year ending June 30, 2026, with 2,640.97% growth.
Revenue (ttm)
$120.25M
Revenue Growth
+599.21%
P/S Ratio
15.81
Revenue / Employee
$1,113,426
Employees
108
Market Cap
1.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 120.25M | 103.05M | 599.21% |
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 22.79M | 115.31% |
| Jun 30, 2015 | 19.76M | -3.63M | -15.52% |
| Jun 30, 2014 | 23.39M | -8.33M | -26.26% |
| Jun 30, 2013 | 31.72M | -7.41M | -18.93% |
| Jun 30, 2012 | 39.12M | -90.48M | -69.81% |
| Jun 30, 2011 | 129.60M | 128.97M | 20,433.19% |
| Jun 30, 2010 | 631.18K | -89.51K | -12.42% |
| Jun 30, 2009 | 720.69K | -152.06K | -17.42% |
| Jun 30, 2008 | 872.75K | -553.16K | -38.79% |
| Jun 30, 2007 | 1.43M | -669.68K | -31.96% |
| Jun 30, 2006 | 2.10M | 1.71M | 447.74% |
| Jun 30, 2005 | 382.59K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.67B |
| Sarepta Therapeutics | 1.97B |
| Lakefront Biotherapeutics NV | 1.13B |
| Vericel | 306.30M |
| Maravai LifeSciences Holdings | 208.78M |
| Septerna | 98.88M |
| Zymeworks | 37.13M |
| Immunome | 4.02M |
MESO News
- 23 hours ago - Mesoblast Limited Announces Board Retirements and Committee Leadership Changes Ahead of 2026 Annual General Meeting - Nasdaq
- 2 days ago - Mesoblast announces changes, retirement of certain members of its Board - TheFly
- 2 days ago - Mesoblast Board Changes - GlobeNewsWire
- 5 days ago - Mesoblast Limited Reports first quarter FY2027 Activity with 44% increase in net revenues - Nasdaq
- 5 days ago - Mesoblast Stock Jumps 17% on Nasdaq as Ryoncil Sales Climb 44% and Cash Burn Collapses in Quarterly Update - International Business Times (Australia)
- 6 days ago - Mesoblast Shares Soar 23% as Ryoncil Revenue Jumps 44% and Cash Burn Plunges 86% in Upbeat Quarterly Update - International Business Times (Australia)
- 6 days ago - Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) - GlobeNewsWire
- 6 days ago - Mesoblast Earnings release: Q1 2027 - Filings